Abstract
BackgroundIn lymphoid malignancies, the introduction of chimeric antigen receptor T (CAR-T) cells and bispecific antibodies (bsAbs) has achieved remarkable clinical success. However, such immunotherapeutic strategies are not yet established for...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have